Search

Your search keyword '"Eghbali H"' showing total 336 results
Start Over Author "Eghbali H"
336 results on '"Eghbali H"'

3. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study

Author

van der Kaaij, M.A.E., van Echten-Arends, J., Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M.P., Noordijk, E.M., Fermé, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G.J.M., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L.M., Casasnovas, O., André, M., Raemaekers, J.M.M., Henry-Amar, M., and Kluin-Nelemans, J.C.

Published
2014
Full Text
View/download PDF

4. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials

Author

Franklin, J., Pluetschow, A., Paus, M., Specht, L., Anselmo, A.-P., Aviles, A., Biti, G., Bogatyreva, T., Bonadonna, G., Brillant, C., Cavalieri, E., Diehl, V., Eghbali, H., Fermé, C., Henry-Amar, M., Hoppe, R., Howard, S., Meyer, R., Niedzwiecki, D., Pavlovsky, S., Radford, J., Raemaekers, J., Ryder, D., Schiller, P., Shakhtarina, S., Valagussa, P., Wilimas, J., and Yahalom, J.

Published
2006
Full Text
View/download PDF

10. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Etude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Author

Ferme, C., Thomas, J, Brice, P., Casasnovas, O., Vranovsky, A., Bologna, S., Lugtenburg, P.J., Bouabdallah, R., Carde, P., Sebban, C., Eghbali, H., Salles, G., Imhoff, G.W. van, Thyss, A., Noordijk, E.M., Reman, O., Lybeert, M.L., Janvier, M., Spina, M., Audhuy, B., Raemaekers, J.M.M., Delarue, R., Anglaret, B., Weerdt, O. de, Marjanovic, Z., Tersteeg, R., Briere, J., Henry-Amar, M., Ferme, C., Thomas, J, Brice, P., Casasnovas, O., Vranovsky, A., Bologna, S., Lugtenburg, P.J., Bouabdallah, R., Carde, P., Sebban, C., Eghbali, H., Salles, G., Imhoff, G.W. van, Thyss, A., Noordijk, E.M., Reman, O., Lybeert, M.L., Janvier, M., Spina, M., Audhuy, B., Raemaekers, J.M.M., Delarue, R., Anglaret, B., Weerdt, O. de, Marjanovic, Z., Tersteeg, R., Briere, J., and Henry-Amar, M.

Abstract

Item does not contain fulltext, PURPOSE: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and the number of cycles to be delivered remain to settle down. The H9-U trial compared three modalities of chemotherapy followed by involved-field radiotherapy (IFRT) in patients with stage I-II HL and risk factors (NCT00005584). PATIENTS AND METHODS: Patients aged 15-70 years with untreated supradiaphragmatic HL with at least one risk factor (age >/= 50, involvement of 4-5 nodal areas, mediastinum/thoracic ratio >/= 0.35, erythrocyte sedimentation rate (ESR) >/= 50 without B-symptoms or ESR >/= 30 and B-symptoms) were eligible for the randomised, open label, multicentre, non-inferiority H9-U trial. The limit of non-inferiority was set at 10% for the difference between 5-year event-free survival (EFS) estimates. From October 1998 to September 2002, 808 patients were randomised to receive either the control arm 6-ABVD-IFRT (n = 276), or one of the two experimental arms: 4-ABVD-IFRT (n = 277) or 4-BEACOPPbaseline-IFRT (n = 255). RESULTS: Results in the 4-ABVD-IFRT (5-year EFS, 85.9%) and the 4-BEACOPPbaseline-IFRT (5-year EFS, 88.8%) were not inferior to 6-ABVD-IFRT (5-year EFS, 89.9%): difference of 4.0% (90%CI, -0.7%-8.8%) and of 1.1% (90%CI,-3.5%-5.6%) respectively. The 5-year overall survival estimates were 94%, 93%, and 93%, respectively. Patients treated with combined modality treatment chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vincristine (Oncovin), cyclophosphamide, procarbazine, etoposide and prednisone (BEACOPP)baseline more often developed serious adverse events requiring supportive measures and hospitalisation compared with patients receiving the chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD). CONCLUSIONS: The trial demonstrates that 4-ABVD followed by IFRT yields high disease control in patients with early-stage HL and risk factors responding to chemotherapy. Although non-inferior in term

Published
2017

11. Quality of Life During and After Treatment of Hodgkin’s Disease

Author

Hœrni, B., Eghbali, H., Herfarth, Ch., editor, Senn, H.-J., editor, Baum, M., editor, Diehl, V., editor, Grundmann, E., editor, Gutzwiller, F., editor, Hitzig, W., editor, Rajewsky, M. F., editor, Wannenmacher, M., editor, Diehl, Volker, editor, Pfreundschuh, Michael, editor, and Loeffler, Markus, editor

Published
1989
Full Text
View/download PDF

12. Maintenance Immunotherapy with BCG in Non-Hodgkin’s Malignant Lymphomas: A Progress Report of a Randomized Trial

Author

Hœrni, B., Durand, M., Eghbali, H., Hœrni-Simon, G., Richaud, P., de Mascarel, A., Allfrey, V. G., editor, Allgöwer, M., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bock, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Porta, G. Della, editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Macbeth, R. A., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Senn, H. J., editor, Bonadonna, G., editor, and Salmon, S., editor

Published
1982
Full Text
View/download PDF

13. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

Author

Eichhorst, Barbara F, Fischer, Kirsten, Fink, Anna Maria, Elter, Thomas, Wendtner, Clemens M, Goede, Valentin, Bergmann, Manuela, Stilgenbauer, Stephan, Hopfinger, Georg, Ritgen, Matthias, Bahlo, Jasmin, Busch, Raymonde, Hallek, Michael, Oduncu, F, Dreyling, M, Forstpointner, R, Schneller, F, Bogner, C, Peschel, C, Ringshausen, I, Götze, K, Goebeler, Me, Rückle, Lanz, Ritgen, M, Schawitzke, A, Heydrich, B, Kern, K, Böttcher, S, Irmer, S, Strack, U, Borries, V, Klima, Km, Scholz, C, Herold, M, Härtwig, K, Dürig, J, Dührsen, U, Müller Beissenhirtz, H, Noppeney, R, Schüttrumpf, S, Hohloch, K, Binder, C, Hasenkamp, J, Trümper, L, Bäsecke, J, Rieger, M, Witzens Harig, M, Friedrichs, B, Rieger, K, Uharek, L, Kubuschok, B, Murawski, N, Held, G, Zwick, C, Pfreundschuh, M, Fingerle Rowson, G, Reiser, M, Elter, T, Eichhorst, B, Pallasch, C, Hallek, M, Borchmann, P, Hacker, U, Schinkel, S, Wieker, K, Sökler, M, Wolf, Hh, Eucker, J, Staib, P, Schlegel, F, Kropff, M, Kahl, C, Hess, G, Beck, J, Wölfel, T, Bokemeyer, C, Schilling, G, Dierlamm, J, Schüler, F, Busemann, C, Dölken, G, Trendelenburg, Tk, Bühler, A, Stilgenbauer, S, Viardot, A, Greiner, J, Zenz, T, Gaidzik, V, Langer, C, Döhner, H, Werner, I, Dienst, A, Habersang, K, Härtel, N, Leitner, A, Kehrer, G, Middeke, H, Heinisch, K, Adorf, D, Ismer, B, Hering Schubert, C, Jäckle, J, Aulmann, C, Söllner, S, Majunke, P, Fuss, H, Käfer, G, Potenberg, J, Dietrich, G, Hartung, E, Pronath, A, Riedhammer, Fj, Zehrfeld, T, Prümmer, O, Gatter, J, Meier, A, Wattad, M, Heit, W, Sauer, I, Hilgers, K, Geissler, M, Bauer, J, Stein, W, Voigtmann, R, Natt, F, Nickelsen, M, Zeis, M, Schmitz, N, Lange, E, Stoltefuss, A, Schubert, J, Dürk, Ha, Kloke, O, Fauser, A, Roemer, E, Kraut, L, Musch, E, Kohl, S, Link, H, Kirsch, Jf, Schatz, M, Mezger, J, Kempf, B, Heil, G, Derigs, Hg, Roll, C, Kettner, E, Dübbers, Hw, Lutz, L, Hentrich, M, Hoffmann, U, Ibe, M, Falge, C, Schäfer Eckart, K, Rothmann, F, Raghavachar, A, Beckmann, K, Behringer, D, Stauder, H, Hempfling, C, Matzdorff, A, Hähling, D, Kaesberger, Kj, Mück, R, Waladkhani, Ar, Clemens, M, Kraft, J, Ehlert, T, N. N., Schloen, A, Sandritter, B, Scholz, Diekmann, C, Pflüger, Kh, Hausner, G, Fetscher, S, Aulitzky, W, Brugger, W, Frickhofen, N, Fuhr, Lange, C, Lambertz, H, Schulz, L, Schmier, M, Bentz, M, Tauchmann, Gm, Schmidt, M, Meiler, J, Sandmann, M, Kürschner, D, Maier Bay, B, Lindemann, W, Diers, J, Riemeier Sievers, C, Daun, M, Mergenthaler, Hg, Hiller, S, Schirmer, V, Kirchner, H, Langer, W, Günther, B, Gassmann, W, Franke, K, Burghardt, F, Abele, U, Celikel Becker, D, von Weikersthal LF, Brög, G, Hauch, U, Heinrich, B, Brudler, O, Häcker, B, Eckart, Mj, Bolouri, H, Göttler, B, Kindler, M, Zuchold, K, Strohbach, F, Plingen, Ml, Seibt Jung, H, Kirsch, A, Herrenberger, J, Doering, G, von Grünhagen, U, Franke, H, Weniger, J, Kerzel, W, Schmalfeld, M, Rohrberg, R, Hurtz, Hj, Gehbauer, G, Hahnfeld, S, Vehling Kaiser, U, Abenhardt, W, Bosse, D, Böning, L, Schmidt, B, Schick, Hd, Jacobs, G, Stauch, M, Hoffmann, R, Müller, S, Hahn, M, Freier, W, Dietzfelbinger, H, Rassmann, I, Söling, U, Siehl, S, Rudolph, R, Weinert, R, Sauer, A, Meyer, B, Eschenburg, H, Schadeck Gressel, C, Grabenhorst, U, Perker, M, Otremba, B, Reschke, D, Hinrichs, Hf, Zirpel, I, Höring, E, Respondek, M, Köppler, H, Heymanns, J, Weide, R, Hünermund, K, Thiel, C, Reiber, T, Spohn, C, Springer, G, Fiechtner, H, Hübner, A, Kurschel, E, Weiss, J, Schlag, R, Schäfer, E, Hartwich, G, Schmitz, S, Steinmetz, T, Kim, Ts, Lerchenmüller, C, Wehmeyer, J, Laubenstein, Hp, Rendenbach, B, Lebahn, H, Kröning, H, Uhle, R, Balló, H, Gaede, B, Zumbrink, S, Eckert, R, Kamp, T, Reimann, B, Burkhard, O, Mittermüller, J, Hansen, R, Hitz, H, Schliesser, G, Schmitt, Hr, Forstbauer, H, Grundeis, M, Schulze, M, Baldus, M, Lakner, V, Haen, M, Müller, C, Dörfel, S, Göhler, T, Welslau, M, Achtzehn, V, Culmann, H, Gerhardt, S, Ulshöfer, T, Koschuth, A, Schmidt, P, Müller, L, Schneider, M, Koniczek, K, Porowski, P, Glados, M, Knoblich, J, Ben Yehuda, D, Jäger, U, Gaiger, A, Schwarzmeier, J, Nösslinger, T, Smith, M, Patton, N, Gibbons, S, Bouabdallah, R, Gandhi, M, Marlton, P, Mills, T, Angelucci, E, Sorano, Gg, Casula, P, Berneman, Z, Kohser, P, Hudcova Burgetova, A, Machová, R, Papajik, T, Kubová, Z, Fineman, R, Mayer, J, Doubek, M, Brychtova, Y, Ciceri, F, Caligaris Cappio, F, Crocchiolo, R, Dauriac, C, Bernard, M, Escoffre Barbe, M, Lamy, T, Zikesova, E, Karban, J, Salkova, J, Trnený, M, Pytlik, R, Tiley, C, Forsyth, C, Vokurka, S, Koza, V, Van Hoof, A, Selleslag, D, Sebban, C, Baker, B, Belada, D, Jebavy, L, Smolej, L, Pavel, Z, Di Ianni, M, Castaigne, S, Del Poeta, G, Amadori, S, Catalano, J, Ganju, V, Hertzberg, M, Laurenti, L, Dalseg, Am, Bron, D, Morton, J, Durrant, S, Casado, Lf, Theunissen, K, Atias, D, Berkhan, L, Seymour, J, Wolf, M, Bosly, A, Osma Cordoba MM, Portois, C, Jaubert, J, Ferrant, A, Lambert, C, Maerevoet, E, Van den Neste, E, Gadeberg, O, Carney, B, Cannell, P, Eghbali, H, Legouffe, E, Bordessoule, D, Chaury, M, Moreau, S, Pierri, I, Gobbi, M, Berrebi, A, Lishner, M, Yerushazim, R, Yermiaku, T, Kosolov, V, Ambrosetti, Achille, Andreoli, Al, Huguet, F, Laurent, G, Orsucci, L, Forconi, F, Musuraca, G, Zinzani, Pl, Loscertales, J, Mcquillan, A, Cordingley, F, Leahy, M, Cazin, B, Taylor, Mulligan, S, Herbrecht, Cull, G, Seldon, M, Rowlings, P, Ludwig, H, Zojer, N, Solal Céligny, P, Pomponi, F, Savdkova, L, Kozák, T, Christiansen, I, Pérez, I, Campbell, P, Canales Albendea, M, De Paz, R, Arthur, C, Gisselbrecht, C., Eichhorst B.F., Fischer K., Fink A.M., Elter T., Wendtner C.M., Goede V., Bergmann M., Stilgenbauer S., Hopfinger G., Ritgen M., Bahlo J., Busch R., Hallek M., and Zinzani P.L.

Subjects
Male, medicine.medical_specialty, Cyclophosphamide, Chronic lymphocytic leukemia, Immunology, Medizin, Antineoplastic Combined Chemotherapy Protocols, Blood Cell Count, Disease Progression, Disease-Free Survival, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Prognosis, Recurrence, Remission Induction, Tomography, X-Ray Computed, Physical examination, Biochemistry, Chemoimmunotherapy, medicine, Chronic, Tomography, Leukemia, medicine.diagnostic_test, business.industry, B-Cell, Cancer, Cell Biology, Hematology, medicine.disease, Lymphocytic, imaging techniques, X-Ray Computed, Fludarabine, Surgery, chronic lymphocytic leukemia, Radiology, business, Progressive disease, medicine.drug
Abstract

The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918.

Published
2011

14. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54)

Author

Aurer, I., Eghbali, H., Raemaekers, J.M., Khaled, H.M., Fortpied, C., Baila, L., and Maazen, R.W. van der

Subjects
genetic structures, Translational research [ONCOL 3], immune system diseases, hemic and lymphatic diseases, polycyclic compounds, Aetiology, screening and detection [ONCOL 5], eye diseases
Abstract

Item does not contain fulltext BACKGROUND: Despite recent improvements, many patients with aggressive non-Hodgkin's lymphoma (NHL) ultimately succumb to their disease. Therefore, improvements in front-line chemotherapy of aggressive NHL are needed. Gemcitabine is active in lymphoma. METHODS: We performed a randomized phase II trial of the addition of gemcitabine to standard CHOP chemotherapy with or without rituximab [(R)CHOP]. The trial was also designed to determine the maximal tolerated dose (MTD) of gemcitabine in this combination. Patients with previously untreated aggressive NHL were randomized to receive either eight cycles of (R)CHOP given every 3 wk or (R)CHOP combined with gemcitabine [Gem-(R)CHOP]. RESULTS: Twenty-five patients were enrolled in the trial before early closure. Twelve were randomized to Gem-(R)CHOP and 13 to (R)CHOP. MTD of gemcitabine was 800 mg/m(2) given on days 1 and 8; dose-limiting toxicity was hematologic. Five patients (42%) treated with Gem-(R)CHOP achieved complete response in comparison with 10 (77%) treated with (R)CHOP. Median time to treatment failure was 1.5 yr for Gem-(R)CHOP and 3.1 yr for (R)CHOP. Three patients receiving Gem-(R)CHOP had serious pulmonary toxicity, when compared to none receiving (R)CHOP. One patient died of pneumonitis. CONCLUSIONS: In this group of patients, addition of gemcitabine did not seem to improve outcomes. Gem-(R)CHOP in previously untreated patients with aggressive NHL occasionally results in severe, potentially fatal, pulmonary toxicity.

Published
2011

16. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study

Author

Kaaij, M.A.E. van der, Echten-Arends, J. van, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M.P., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G.J.M., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L.M., Casasnovas, O., Andre, M., Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, J.C., European Org Res Treatment Canc, Grp Etud Lymphomes Adulte, Centre d’études des transformations des activités physiques et sportives (CETAPS), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut de Recherche Interdisciplinaire Homme et Société (IRIHS), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Ecole Polytech Fed Lausanne, Lab Phys Complex Matter, CH-1015 Lausanne, Switzerland, Department of neurology, Leiden University Medical Center (LUMC), Centre de génétique et de physiologie moléculaire et cellulaire (CGPhiMC), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR), Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Swedish Institute of Space Physics [Uppsala] (IRF), European Organisation for Research and Treatment of Cancer Lymphoma Group, Groupe d'Étude des Lymphomes de l'Adulte, Hematology, Internal medicine, CCA - Quality of life, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Stem Cell Aging Leukemia and Lymphoma (SALL)

Subjects
[SDV]Life Sciences [q-bio], cryopreservation, Cryopreservation, DISEASE, law.invention, Cohort Studies, Randomized controlled trial, law, Survivors, Fertility preservation, Child, ComputingMilieux_MISCELLANEOUS, media_common, fertility, Rehabilitation, Age Factors, Obstetrics and Gynecology, MEN, Middle Aged, Hodgkin Disease, Semen cryopreservation, 3. Good health, TRIALS, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Cohort study, Adult, medicine.medical_specialty, Adolescent, media_common.quotation_subject, [SDV.CAN]Life Sciences [q-bio]/Cancer, Fertility, Semen, lymphoma, CANCER-PATIENTS, TESTICULAR CANCER, SDG 3 - Good Health and Well-being, male, Hodgkin, Internal medicine, medicine, Humans, QUALITY, BANKING, Biology, Aged, SPERM CRYOPRESERVATION, Gynecology, business.industry, Odds ratio, Reproductive Medicine, EXPERIENCE, Human medicine, business, FERTILITY PRESERVATION, Semen Preservation
Abstract

Contains fulltext : 137720.pdf (Publisher’s version ) (Closed access) STUDY QUESTION: How does the successful cryopreservation of semen affect the odds of post-treatment fatherhood among Hodgkin lymphoma (HL) survivors? SUMMARY ANSWER: Among 334 survivors who wanted to have children, the availability of cryopreserved semen doubled the odds of post-treatment fatherhood. WHAT IS KNOWN ALREADY: Cryopreservation of semen is the easiest, safest and most accessible way to safeguard fertility in male patients facing cancer treatment. Little is known about what proportion of patients achieve successful semen cryopreservation. To our knowledge, neither the factors which influence the occurrence of semen cryopreservation nor the rates of fatherhood after semen has been cryopreserved have been analysed before. STUDY DESIGN, SIZE, DURATION: This is a cohort study with nested case-control analyses of consecutive Hodgkin survivors treated between 1974 and 2004 in multi-centre randomized controlled trials. A written questionnaire was developed and sent to 1849 male survivors. PARTICIPANTS/MATERIALS, SETTING, METHODS: Nine hundred and two survivors provided analysable answers. The median age at treatment was 31 years. The median follow-up after cryopreservation was 13 years (range 5-36). MAIN RESULTS AND THE ROLE OF CHANCE: Three hundred and sixty-three out of 902 men (40%) cryopreserved semen before the start of potentially gonadotoxic treatment. The likelihood of semen cryopreservation was influenced by age, treatment period, disease stage, treatment modality and education level. Seventy eight of 363 men (21%) used their cryopreserved semen. Men treated between 1994 and 2004 had significantly lower odds of cryopreserved semen use compared with those treated earlier, whereas alkylating or second-line (chemo)therapy significantly increased the odds of use; no other influencing factors were identified. We found an adjusted odds ratio of 2.03 (95% confidence interval 1.11-3.73, P = 0.02) for post-treatment fatherhood if semen cryopreservation was performed. Forty-eight out of 258 men (19%) who had children after HL treatment became a father using cryopreserved semen. LIMITATIONS, REASONS FOR CAUTION: Data came from questionnaires and so this study potentially suffers from response bias. We could not perform an analysis with correction for duration of follow-up or provide an actuarial use rate due to lack of dates of semen utilization. We do not have detailed information on either the techniques used in cryopreserved semen utilization or the number of cycles needed. STUDY FUNDING/COMPETING INTERESTS: Lance Armstrong Foundation, Dutch Cancer Foundation, Rene Vogels Stichting, no competing interests.

Published
2014

17. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Author

Deshmukh C.D., Offner F., Van Den Neste E.W., Wu K.L., Van Hoof A., Maiolino A., Pinczowski H., Zanichelli M.A., Pereira J., Larratt L., Spaner D., Howson-Jan K., Chen C.I., Cantin G., Fernandez L.A., Fraser G., Mayer J., Trneny M., Jebavy L., Bordessoule D., Lamy T., Milpied N., Truchan-Graczyk M., Eghbali H., Karsenti J.-M., Celigny P.S., Mans L., Cazin B., Gyan E., Lepretre S., Bergmann L., Tsionos K., Lokeshwar N.M., Agarwal M.B., Ross C.R., Narayanan G., Raina V., Bondarde S.A., Shah B.A., Bairey O., Tikva P., Shvidel L., Ambrosetti A., Rossi P.G.B., Angelucci E., Carella A.M., Massaia M., Zinzani P.L., Caligaris-Cappio F., Foa R., Gaidano G., della Carita A.O.M., Leone G., Santoro A., Griskevicius L., Jurgutis R., Baker B.W., Hawkins T., Corbett G.M., Ganly P., D'Souza A.B., Deptala A., Holowiecki J., Kloczko J., Skotnicki A., Zdziarska B., Kyrcz-Krzemien S., Dmoszynska A., Moreira I., Pereira A.P., Colita A., Moicean A.D., Vasilica M., Danaila C., Gheorghita E., Pavlov V.V., Rossiev V.A., Konstantinova T., Samoilova O.S., Novgorod N., Shelekhova T., Zaritsky A.Y., Abdulkadyrov K.M., Zyuzgin I.S., Pristupa A.S., Loscertales J., Vidal J.B., de Mallorca P., Gonzalez M., Ortuno F., Giraldo P., Nathwani A., Agrawal S.G., Rule S., Dearden C.E., Bloor A.J., Haynes A., Singer C., Boclek R.G., Bosserman L.D., Chan D., Davidson S.J., Dichmann R.A., Farber C., Hart L., Hermann R., Hu E., Janakiraman N., Jonas W., Liem K.D., Mcintyre R.E., O'Brien S., Patel G., Rado T., Schilder R., Smith S.E., Stock W., Turturro F., Venugopal P., Anderson T.C., Berry W., Boyd T.E., Byrd J., Cooper M., Flinn I., Gersh R., Gordon D., Guzley G.J., Wilks S.T., Klein A., Krauss J.C., Lister J., Mandell L., Molina A., Cooper B., Pendergrass K.B., Reeder C., Savin M.A., Spitzer G., Tuscano J.M., vanDeventer H., Eradat H.A., Masood A., Mena R., Awan F.T., Hillmen P., Hellmann A., Robak T., Hughes S.G., Trone D., Shannon M., Flinn I.W., Byrd J.C., Riveros D., Pavlovsky S., Iastrebner C.M., Carney D.A., Deveridge S., Durrant S., Hahn U.H., Hertzberg M., Leahy M.F., Ma D., Marlton P., Mulligan S., Opat S.S., Tiley C., Wickham N.W., Cannell P., Gatalano J., Catalano J., Cull G., To L.B., Hopfinger G., Jager U., Linkesch W., Petzer A., Schwarzmeier J., Steurer M., Greil R., Bememan Z., Bosly A., Bron D., Janssens A., Deshmukh C.D., Offner F., Van Den Neste E.W., Wu K.L., Van Hoof A., Maiolino A., Pinczowski H., Zanichelli M.A., Pereira J., Larratt L., Spaner D., Howson-Jan K., Chen C.I., Cantin G., Fernandez L.A., Fraser G., Mayer J., Trneny M., Jebavy L., Bordessoule D., Lamy T., Milpied N., Truchan-Graczyk M., Eghbali H., Karsenti J.-M., Celigny P.S., Mans L., Cazin B., Gyan E., Lepretre S., Bergmann L., Tsionos K., Lokeshwar N.M., Agarwal M.B., Ross C.R., Narayanan G., Raina V., Bondarde S.A., Shah B.A., Bairey O., Tikva P., Shvidel L., Ambrosetti A., Rossi P.G.B., Angelucci E., Carella A.M., Massaia M., Zinzani P.L., Caligaris-Cappio F., Foa R., Gaidano G., della Carita A.O.M., Leone G., Santoro A., Griskevicius L., Jurgutis R., Baker B.W., Hawkins T., Corbett G.M., Ganly P., D'Souza A.B., Deptala A., Holowiecki J., Kloczko J., Skotnicki A., Zdziarska B., Kyrcz-Krzemien S., Dmoszynska A., Moreira I., Pereira A.P., Colita A., Moicean A.D., Vasilica M., Danaila C., Gheorghita E., Pavlov V.V., Rossiev V.A., Konstantinova T., Samoilova O.S., Novgorod N., Shelekhova T., Zaritsky A.Y., Abdulkadyrov K.M., Zyuzgin I.S., Pristupa A.S., Loscertales J., Vidal J.B., de Mallorca P., Gonzalez M., Ortuno F., Giraldo P., Nathwani A., Agrawal S.G., Rule S., Dearden C.E., Bloor A.J., Haynes A., Singer C., Boclek R.G., Bosserman L.D., Chan D., Davidson S.J., Dichmann R.A., Farber C., Hart L., Hermann R., Hu E., Janakiraman N., Jonas W., Liem K.D., Mcintyre R.E., O'Brien S., Patel G., Rado T., Schilder R., Smith S.E., Stock W., Turturro F., Venugopal P., Anderson T.C., Berry W., Boyd T.E., Byrd J., Cooper M., Flinn I., Gersh R., Gordon D., Guzley G.J., Wilks S.T., Klein A., Krauss J.C., Lister J., Mandell L., Molina A., Cooper B., Pendergrass K.B., Reeder C., Savin M.A., Spitzer G., Tuscano J.M., vanDeventer H., Eradat H.A., Masood A., Mena R., Awan F.T., Hillmen P., Hellmann A., Robak T., Hughes S.G., Trone D., Shannon M., Flinn I.W., Byrd J.C., Riveros D., Pavlovsky S., Iastrebner C.M., Carney D.A., Deveridge S., Durrant S., Hahn U.H., Hertzberg M., Leahy M.F., Ma D., Marlton P., Mulligan S., Opat S.S., Tiley C., Wickham N.W., Cannell P., Gatalano J., Catalano J., Cull G., To L.B., Hopfinger G., Jager U., Linkesch W., Petzer A., Schwarzmeier J., Steurer M., Greil R., Bememan Z., Bosly A., Bron D., and Janssens A.

Abstract

Summary: Lumiliximab is a chimeric monoclonal antibody that targets CD23 on the surface of chronic lymphocytic leukaemia (CLL) B-cells. Early phase clinical studies with lumiliximab alone and in combination with fludarabine, cyclophosphamide and rituximab (FCR) established its potential efficacy and tolerability. The 152CL201 trial [Lumiliximab with fludarabine, cyclophosphamide and rituximab (FCR) versus FCR alone in subjects with relapsed CLL; LUCID] was a phase 2/3, randomized (1:1), open-label, multicentre study of lumiliximab in combination with FCR versus FCR alone in patients with relapsed CLL. Six hundred and twenty-seven patients were randomized to either arm. Overall the combination of lumiliximab with FCR was not significantly better than FCR alone (overall response rate 71% vs. 72%, complete response rate 16% vs. 15%, median progression-free survival 24.6 vs. 23.9 months respectively, for FCR with and without lumiliximab). There was a slightly increased incidence of adverse events with lumiliximab but these increases did not appear to lead to differences in eventual outcomes. An interim analysis failed to show sufficient efficacy of the combination of lumiliximab with FCR. The study was therefore stopped early for lack of efficacy. Despite the eventual outcome, the LUCID trial is one of the largest studies that provides valuable insight into the efficacy and tolerability of FCR as a therapeutic option for patients with relapsed CLL.Copyright © 2014 John Wiley & Sons Ltd.

Published
2015

20. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: An EORTC-GELA lymphoma group cohort study

Author

UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Van Der Kaaij, M.A.E., Van Echten-Arends, J., Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M.P., Noordijk, E.M., Fermé, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G.J.M., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L.M., Casasnovas, O., André, Marc, Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, J.C., UCL - (MGD) Service d'hématologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, Van Der Kaaij, M.A.E., Van Echten-Arends, J., Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M.P., Noordijk, E.M., Fermé, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G.J.M., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L.M., Casasnovas, O., André, Marc, Raemaekers, J.M.M., Henry-Amar, M., and Kluin-Nelemans, J.C.

Abstract

STUDY QUESTIONHow does the successful cryopreservation of semen affect the odds of post-treatment fatherhood among Hodgkin lymphoma (HL) survivors?SUMMARY ANSWERAmong 334 survivors who wanted to have children, the availability of cryopreserved semen doubled the odds of post-treatment fatherhood.WHAT IS KNOWN ALREADYCryopreservation of semen is the easiest, safest and most accessible way to safeguard fertility in male patients facing cancer treatment. Little is known about what proportion of patients achieve successful semen cryopreservation. To our knowledge, neither the factors which influence the occurrence of semen cryopreservation nor the rates of fatherhood after semen has been cryopreserved have been analysed before.STUDY DESIGN, SIZE, DURATIONThis is a cohort study with nested case-control analyses of consecutive Hodgkin survivors treated between 1974 and 2004 in multi-centre randomized controlled trials. A written questionnaire was developed and sent to 1849 male survivors.PARTICIPANTS/ MATERIALS, SETTING, METHODSNine hundred and two survivors provided analysable answers. The median age at treatment was 31 years. The median follow-up after cryopreservation was 13 years (range 5-36).MAIN RESULTS AND THE ROLE OF CHANCEThree hundred and sixty-three out of 902 men (40%) cryopreserved semen before the start of potentially gonadotoxic treatment. The likelihood of semen cryopreservation was influenced by age, treatment period, disease stage, treatment modality and education level. Seventy eight of 363 men (21%) used their cryopreserved semen. Men treated between 1994 and 2004 had significantly lower odds of cryopreserved semen use compared with those treated earlier, whereas alkylating or second-line (chemo)therapy significantly increased the odds of use; no other influencing factors were identified. We found an adjusted odds ratio of 2.03 (95% confidence interval 1.11-3.73, P = 0.02) for post-treatment fatherhood if semen cryopreservation was performed. Forty-eigh

Published
2014

21. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study

Author

Kaaij, M.A. van der, Echten-Arends, J. van, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L., Casasnovas, O., Andre, M., Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, J.C., et al., Kaaij, M.A. van der, Echten-Arends, J. van, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L., Casasnovas, O., Andre, M., Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, J.C., and et al.

Abstract

Contains fulltext : 137720.pdf (publisher's version ) (Closed access), STUDY QUESTION: How does the successful cryopreservation of semen affect the odds of post-treatment fatherhood among Hodgkin lymphoma (HL) survivors? SUMMARY ANSWER: Among 334 survivors who wanted to have children, the availability of cryopreserved semen doubled the odds of post-treatment fatherhood. WHAT IS KNOWN ALREADY: Cryopreservation of semen is the easiest, safest and most accessible way to safeguard fertility in male patients facing cancer treatment. Little is known about what proportion of patients achieve successful semen cryopreservation. To our knowledge, neither the factors which influence the occurrence of semen cryopreservation nor the rates of fatherhood after semen has been cryopreserved have been analysed before. STUDY DESIGN, SIZE, DURATION: This is a cohort study with nested case-control analyses of consecutive Hodgkin survivors treated between 1974 and 2004 in multi-centre randomized controlled trials. A written questionnaire was developed and sent to 1849 male survivors. PARTICIPANTS/MATERIALS, SETTING, METHODS: Nine hundred and two survivors provided analysable answers. The median age at treatment was 31 years. The median follow-up after cryopreservation was 13 years (range 5-36). MAIN RESULTS AND THE ROLE OF CHANCE: Three hundred and sixty-three out of 902 men (40%) cryopreserved semen before the start of potentially gonadotoxic treatment. The likelihood of semen cryopreservation was influenced by age, treatment period, disease stage, treatment modality and education level. Seventy eight of 363 men (21%) used their cryopreserved semen. Men treated between 1994 and 2004 had significantly lower odds of cryopreserved semen use compared with those treated earlier, whereas alkylating or second-line (chemo)therapy significantly increased the odds of use; no other influencing factors were identified. We found an adjusted odds ratio of 2.03 (95% confidence interval 1.11-3.73, P = 0.02) for post-treatment fatherhood if semen cryopreservation was perfo

Published
2014

27. Extending the functionalities of shear-driven chromatography nano-channels using high aspect ratio etching

Author

de Malsche, Wim, Clicq, D., Eghbali, H., Vervoort, N., Gardeniers, Johannes G.E., van den Berg, Albert, Desmet, G., Jensen, K.F, Han, J., Harrisson, D.J., Voldman, J., Faculty of Science and Technology, and Mesoscale Chemical Systems

Subjects
high aspect ratio etching, Nanochannels, technology, industry, and agriculture, METIS-224675, IR-52860, Computational Fluid Dynamics, injection system, EWI-18739, Shear-driven chromatography
Abstract

An new injection system is presented for shear-driven chromatography. The device has been fabricated by high aspect ratio etching of silicon. The performance of the injection slit is studied through the aid of computational fluid dynamics, and the first experimental results are presented.

Published
2005

30. Involved-field radiotherapy for advanced Hodgkin's lymphoma

Author

Aleman, BMP, Raemaekers, JMM, Tirelli, U, Bortolus, R, van't Veer, MB, Lybeert, MLM, Keuning, JJ, Carde, P, Girinsky, T, van der Maazen, RWM, Tomsic, R, Vovk, M, van Hoof, A, Demeestere, G, Lugtenburg, PJ, Schroyens, W, De Boeck, K, Baars, JW, Kluin-Nelemans, JC, Carrie, C, Aoudjhane, M, Bron, D, Eghbali, H, Smit, WGJM, Meerwaldt, JH, Hagenbeek, A, Pinna, A, Henry-Amar, M, Damage and Repair in Cancer Development and Cancer Treatment (DARE), and Stem Cell Aging Leukemia and Lymphoma (SALL)

Subjects
RISK, 6 CYCLES, 2ND MALIGNANCY, DETUDES-DES-LYMPHOMES, LADULTE H89 TRIAL, ALTERNATING CHEMOTHERAPY, ALKYLATING-AGENTS, COOPERATIVE GROUP, SALVAGE THERAPY, DISEASE
Abstract

Background: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. Methods: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV) to receive either no further treatment or involved-field radiotherapy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites. Patients in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites. Results: Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to no further treatment, and 172 to involved-field radiotherapy. The median follow-up was 79 months. The five-year event-free survival rate was 84 percent in the group that did not receive radiotherapy and 79 percent in the group that received involved-field radiotherapy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively (P=0.07). Among the 250 patients in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively. Conclusions: Involved-field radiotherapy did not improve the outcome in patients with advanced-stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy. Radiotherapy may benefit patients with a partial response after chemotherapy.

Published
2003

31. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study

Author

van der Kaaij, M.A.E., primary, van Echten-Arends, J., additional, Heutte, N., additional, Meijnders, P., additional, Abeilard-Lemoisson, E., additional, Spina, M., additional, Moser, E.C., additional, Allgeier, A., additional, Meulemans, B., additional, Lugtenburg, P.J., additional, Aleman, B.M.P., additional, Noordijk, E.M., additional, Fermé, C., additional, Thomas, J., additional, Stamatoullas, A., additional, Fruchart, C., additional, Eghbali, H., additional, Brice, P., additional, Smit, W.G.J.M., additional, Sebban, C., additional, Doorduijn, J.K., additional, Roesink, J.M., additional, Gaillard, I., additional, Coiffier, B., additional, Lybeert, M.L.M., additional, Casasnovas, O., additional, André, M., additional, Raemaekers, J.M.M., additional, Henry-Amar, M., additional, and Kluin-Nelemans, J.C., additional

Published
2013
Full Text
View/download PDF

32. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.

Author

Kaaij, M.A. van der, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Simons, A.H., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Brice, P., Gaillard, I., Bologna, S., Ong, F., Eghbali, H., Doorduijn, J.K., Morschhauser, F., Sebban, C., Roesink, J.M., Bouteloup, M., Hoof, A. van, Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, H.C., Kaaij, M.A. van der, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Simons, A.H., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Brice, P., Gaillard, I., Bologna, S., Ong, F., Eghbali, H., Doorduijn, J.K., Morschhauser, F., Sebban, C., Roesink, J.M., Bouteloup, M., Hoof, A. van, Raemaekers, J.M.M., Henry-Amar, M., and Kluin-Nelemans, H.C.

Abstract

Contains fulltext : 109132.pdf (publisher's version ) (Open Access), PURPOSE: In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment. PATIENTS AND METHODS: The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis. RESULTS: Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF. CONCLUSION: Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF.

Published
2012

33. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'ÉTude des Lymphomes de l'Adulte Cohort Study

Author

Kaaij, M.A.E. (Marleen A.) van der, Heutte, N. (Natacha), Meijnders, P. (Paul), Abeilard-Lemoisson, E. (Edwige), Spina, M. (Michele), Moser, E.C. (E.), Allgeier, A. (Anouk), Meulemans, B. (Bart), Simons, A.H.M., Lugtenburg, P.J. (Pieternella), Aleman, B.M.P. (Berthe), Noordijk, E.M. (Evert), Fermé, C. (Christophe), Thomas, J. (Jose), Stamatoullas, A. (Aspasia), Fruchart, C. (Christophe), Brice, P. (Pauline), Gaillard, I. (Isabelle), Bologna, S. (Serge), Ong, F. (Francisca), Eghbali, H. (Houchingue), Doorduijn, J.K. (Jeanette), Morschhauser, F. (Frank), Sebban, C. (Catherine), Roesink, J.M. (Judith), Bouteloup, M. (Marie), Hoof, A.L. (Achiel) van, Raemaekers, J. (John), Henry-Amar, M. (Michel), Kluin-Nelemans, J.C. (Hanneke), Kaaij, M.A.E. (Marleen A.) van der, Heutte, N. (Natacha), Meijnders, P. (Paul), Abeilard-Lemoisson, E. (Edwige), Spina, M. (Michele), Moser, E.C. (E.), Allgeier, A. (Anouk), Meulemans, B. (Bart), Simons, A.H.M., Lugtenburg, P.J. (Pieternella), Aleman, B.M.P. (Berthe), Noordijk, E.M. (Evert), Fermé, C. (Christophe), Thomas, J. (Jose), Stamatoullas, A. (Aspasia), Fruchart, C. (Christophe), Brice, P. (Pauline), Gaillard, I. (Isabelle), Bologna, S. (Serge), Ong, F. (Francisca), Eghbali, H. (Houchingue), Doorduijn, J.K. (Jeanette), Morschhauser, F. (Frank), Sebban, C. (Catherine), Roesink, J.M. (Judith), Bouteloup, M. (Marie), Hoof, A.L. (Achiel) van, Raemaekers, J. (John), Henry-Amar, M. (Michel), and Kluin-Nelemans, J.C. (Hanneke)

Abstract

Purpose: In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment. Patients and Methods: The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Étude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis. Results: Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF. Conclusion: Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF.

Published
2012
Full Text
View/download PDF

34. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

Author

Heutte, N., Flechtner, H.H., Mounier, N., Mellink, W.A.M., Meerwaldt, J.H., Eghbali, H., Veer, M.B. van 't, Noordijk, E.M., Kluin-Nelemans, H.C., Lampka, E., Thomas, J., Lugtenburg, P.J., Viterbo, L., Carde, P., Hagenbeek, A., Maazen, R.W.M. van der, Smit, W.G., Brice, P., Marwijk-Kooy, M. van, Baars, J.W., Poortmans, P.M.P., Tirelli, U., Leeksma, O.C., Tomsic, R., Feugier, P., Salles, G., Gabarre, J., Kersten, M.J., Neste, E. van den, Creemers, G.J., Gaillard, I., Meijnders, P., Tertian, G., Reman, O., Muller, H.P., Troncy, J., Blanc, M., Schroyens, W., Voogt, P.J., Wijermans, P., Rieux, C., Ferme, C., Henry-Amar, M., Heutte, N., Flechtner, H.H., Mounier, N., Mellink, W.A.M., Meerwaldt, J.H., Eghbali, H., Veer, M.B. van 't, Noordijk, E.M., Kluin-Nelemans, H.C., Lampka, E., Thomas, J., Lugtenburg, P.J., Viterbo, L., Carde, P., Hagenbeek, A., Maazen, R.W.M. van der, Smit, W.G., Brice, P., Marwijk-Kooy, M. van, Baars, J.W., Poortmans, P.M.P., Tirelli, U., Leeksma, O.C., Tomsic, R., Feugier, P., Salles, G., Gabarre, J., Kersten, M.J., Neste, E. van den, Creemers, G.J., Gaillard, I., Meijnders, P., Tertian, G., Reman, O., Muller, H.P., Troncy, J., Blanc, M., Schroyens, W., Voogt, P.J., Wijermans, P., Rieux, C., Ferme, C., and Henry-Amar, M.

Abstract

Contains fulltext : 81805.pdf (publisher's version ) (Closed access), BACKGROUND: Little is known about the longitudinal course of health-related quality of life (HRQoL) in patients with Hodgkin's lymphoma during their post-treatment follow-up and re-adaptation to normal life. We report on the HRQoL of patients treated in the randomised H8 trial of the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). We aimed to assess HRQoL and fatigue following treatment, to analyse relations with treatment, and to identify factors that predict persistent fatigue. METHODS: Patients received HRQoL questionnaires at the end of primary therapy and during follow-up. The EORTC QLQ-C30 was used to assess HRQoL, and the Multidimensional Fatigue Inventory (MFI-20) was used to assess fatigue. Changes of mean HRQoL scores over time were analysed with mixed models. Multiple polytomic nominal logistic regression was done to identify independent baseline predictors of fatigue within MFI-20 dimensions. Analyses were done on an intention-to-treat basis. This study is registered with www.ClinicalTrials.gov, number NCT00379041. FINDINGS: 2666 assessments from 935 patients were analysed. Mean follow-up was 90 months (range 52-118). Age affected all functioning and symptom scores except emotional functioning, with younger age associated with higher functioning and lower severity of symptoms; improvement with time showed similar patterns between age groups. Women reported lower HRQoL and higher symptom scores than did men. Overall, 3.2% (14/439 for role functioning) to 9.7% (43/442 for social functioning) and 5.8% (29/498 for reduced motivation) to 9.9% (49/498 for general fatigue) of patients reported impairments of 10 points or more (on a 0-100 scale) in QLQ-C30 and MFI-20 scores, respectively, independent of age and sex. Emotional domains were more affected than physical ones. There was no relation between HRQoL outcome and type of treatment. Fatigue (MFI-20 scores) at the end

Published
2009

35. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials.

Author

Kaaij, M.A. van der, Heutte, N., Echten-Arends, J. van, Raemaekers, J.M.M., Carde, P., Noordijk, E.M., Ferme, C., Thomas, J., Eghbali, H., Brice, P., Bonmati, C., Henry-Amar, M., Kluin-Nelemans, H.C., Kaaij, M.A. van der, Heutte, N., Echten-Arends, J. van, Raemaekers, J.M.M., Carde, P., Noordijk, E.M., Ferme, C., Thomas, J., Eghbali, H., Brice, P., Bonmati, C., Henry-Amar, M., and Kluin-Nelemans, H.C.

Abstract

Contains fulltext : 81517.pdf (publisher's version ) (Open Access), BACKGROUND: Although widely recommended, cryopreservation of sperm is sometimes not performed for patients with Hodgkin's lymphoma because of presumed poor sperm quality related to the disease. We investigated sperm quality and factors determining it in untreated patients with early stage Hodgkin's lymphoma. DESIGN AND METHODS: Of 2362 males who participated in EORTC H6-H9 trials, 474 (20%) had data available. Sperm quality was defined according to World Health Organization guidelines. Determining factors were studied by logistic regression analysis. RESULTS: The median sperm concentration was 40x10(6)/mL (range, 0-345x10(6)/mL) and the median motility 50% (range, 0-90%). Sperm quality was good (concentration >or=20x10(6)/mL and motility >or=50%), intermediate (concentration >or=5x10(6)/mL) and poor (concentration <5x10(6)/mL but >0) in 41%, 49% and 7% of patients, respectively. Three percent of the patients were azoospermic. No relation was found between sperm quality and age or clinical stage of the Hodgkin's lymphoma, but B-symptoms and elevated erythrocyte sedimentation rate predicted poor sperm quality. The odds ratios for the association of poor sperm quality with the variables examined were: presence of B-symptoms, 2.77 (95% CI, 1.50-5.12; p=0.001); erythrocyte sedimentation rate of 50 mm/h or greater, 2.35 (95% CI, 1.24-4.43; p=0.009); fever, 3.22 (95% CI, 1.41-7.33; p=0.005), and night sweats, 3.78 (95% CI, 1.97-7.26; p<0.001). There was no relation between sperm quality and pre-treatment follicle stimulating hormone level. CONCLUSIONS: In this large study of males with Hodgkin's lymphoma, 90% had good or intermediate sperm quality. Three percent were azoospermic. There was an association between sperm quality and the presence or absence of B-symptoms, in particular fever and night sweats. With modern fertilization techniques, in most patients with early-stage Hodgkin's lymphoma sperm quality before treatment is good enough for future fatherhood.

Published
2009

36. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Author

Ferme, C., Eghbali, H., Meerwaldt, J.H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., Veer, M.B. van 't, Walewski, J.A., Lederlin, P., Tirelli, U., Carde, P., Neste, E. van den, Gyan, E., Monconduit, M., Divine, M., Raemaekers, J.M.M., Salles, G., Noordijk, E.M., Creemers, G.J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vie, B., Kluin-Nelemans, J.C., Viseu, F., Baars, J.W., Poortmans, P.M.P., Lugtenburg, P., Carrie, C., Jaubert, J., Henry-Amar, M., Ferme, C., Eghbali, H., Meerwaldt, J.H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., Veer, M.B. van 't, Walewski, J.A., Lederlin, P., Tirelli, U., Carde, P., Neste, E. van den, Gyan, E., Monconduit, M., Divine, M., Raemaekers, J.M.M., Salles, G., Noordijk, E.M., Creemers, G.J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vie, B., Kluin-Nelemans, J.C., Viseu, F., Baars, J.W., Poortmans, P.M.P., Lugtenburg, P., Carrie, C., Jaubert, J., and Henry-Amar, M.

Abstract

Item does not contain fulltext, BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P=0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (Clin

Published
2007

37. Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.

Author

Kaaij, M.A. van der, Heutte, N., Stang, N. Le, Raemaekers, J.M.M., Simons, A.H., Carde, P., Noordijk, E.M., Ferme, C., Thomas, J., Eghbali, H., Kluin-Nelemans, H.C., Henry-Amar, M., Kaaij, M.A. van der, Heutte, N., Stang, N. Le, Raemaekers, J.M.M., Simons, A.H., Carde, P., Noordijk, E.M., Ferme, C., Thomas, J., Eghbali, H., Kluin-Nelemans, H.C., and Henry-Amar, M.

Abstract

Contains fulltext : 51705.pdf (publisher's version ) (Open Access), PURPOSE: To analyze fertility in male patients treated with various combinations of radiotherapy and chemotherapy, with or without alkylating agents, or with radiotherapy alone for Hodgkin's lymphoma. PATIENTS AND METHODS: Follicle-stimulating hormone (FSH) levels were measured in patients with early-stage upper-diaphragmatic disease enrolled in four European Organisation for Research and Treatment of Cancer (EORTC) trials (H6-H9). Median follow-up after therapy was 32 months. Patients with FSH measurement at least 12 months after end of treatment (n = 355) were selected to assess post-treatment fertility. Patients with FSH measurement 0 to 9 months after therapy (n = 349) were selected to analyze fertility recovery; of these, patients with elevated FSH (> 10 U/L; n = 101) were followed until recovery. Factors predictive for therapy-related infertility were assessed by logistic regression. RESULTS: The proportion of elevated FSH was 3% and 8% in patients treated with radiotherapy only or with nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine [ABVD], epirubicin, bleomycin, vinblastine, prednisone [EBVP]); it was 60% (P < .001) after chemotherapy containing alkylating agents (mechlorethamine, vincristine, procarbazine, prednisone [MOPP], MOPP/doxorubicin, bleomycin, vinblastine [ABV], bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone [BEACOPP]). After a median time of 19 months, recovery of fertility occurred in 82% of patients treated without alkylating chemotherapy. This proportion was 30%, statistically (P < .001) lower in those treated with alkylating chemotherapy, and median time to recovery was 27 months. The post-treatment proportion of elevated FSH increased significantly (P < .001) with the dose of alkylating chemotherapy administered, and recovery was less frequent and slower after higher doses. Age more than 50 years and stage II disease also contributed to poor outcome. CONCLUSION: Fertili

Published
2007

38. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

Author

Fermé, C. (Christophe), Eghbali, H. (Houchingue), Meerwaldt, J.H. (Jacobus), Rieux, C. (Chantal), Bosq, J. (Jacques), Berger, F. (Françoise), Girinsky, T. (Théodore), Brice, P. (Pauline), Veer, M.B. (Mars) van 't, Walewski, J. (Jan), Lederlin, P. (Pierre), Tirelli, U. (Umberto), Carde, P. (Patrice), Neste, E. (Eric) van den, Gyan, E. (Emmanuel), Monconduit, M. (Mathieu), Diviné, M. (Marine), Raemaekers, J. (John), Salles, G. (Gilles), Noordijk, E.M. (Evert), Creemers, G.J.M. (Geert-Jan), Gabarre, J. (Jean), Hagenbeek, A. (Anton), Reman, O. (Oumédaly), Blanc, M. (Michel), Thomas, J. (Jose), Vié, B. (Brigitte), Kluin-Nelemans, J.C. (Hanneke), Viseu, F. (Fernando), Baars, J.W. (Joke), Poortmans, P.M.P. (Philip), Lugtenburg, P.J. (Pieternella), Carrie, C. (Christian), Jaubert, J. (Jérôme), Henry-Amar, M. (Michel), Fermé, C. (Christophe), Eghbali, H. (Houchingue), Meerwaldt, J.H. (Jacobus), Rieux, C. (Chantal), Bosq, J. (Jacques), Berger, F. (Françoise), Girinsky, T. (Théodore), Brice, P. (Pauline), Veer, M.B. (Mars) van 't, Walewski, J. (Jan), Lederlin, P. (Pierre), Tirelli, U. (Umberto), Carde, P. (Patrice), Neste, E. (Eric) van den, Gyan, E. (Emmanuel), Monconduit, M. (Mathieu), Diviné, M. (Marine), Raemaekers, J. (John), Salles, G. (Gilles), Noordijk, E.M. (Evert), Creemers, G.J.M. (Geert-Jan), Gabarre, J. (Jean), Hagenbeek, A. (Anton), Reman, O. (Oumédaly), Blanc, M. (Michel), Thomas, J. (Jose), Vié, B. (Brigitte), Kluin-Nelemans, J.C. (Hanneke), Viseu, F. (Fernando), Baars, J.W. (Joke), Poortmans, P.M.P. (Philip), Lugtenburg, P.J. (Pieternella), Carrie, C. (Christian), Jaubert, J. (Jérôme), and Henry-Amar, M. (Michel)

Abstract

BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year eventfree survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P = 0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (Cli

Published
2007
Full Text
View/download PDF

39. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Author

Noordijk, E.M., Carde, P., Dupouy, N., Hagenbeek, A., Krol, A.D., Kluin-Nelemans, J.C., Tirelli, U., Monconduit, M., Thomas, J., Eghbali, H., Aleman, B., Bosq, J., Vovk, M., Verschueren, T.A., Peny, A.M., Girinsky, T., Raemaekers, J.M.M., Henry-Amar, M., Noordijk, E.M., Carde, P., Dupouy, N., Hagenbeek, A., Krol, A.D., Kluin-Nelemans, J.C., Tirelli, U., Monconduit, M., Thomas, J., Eghbali, H., Aleman, B., Bosq, J., Vovk, M., Verschueren, T.A., Peny, A.M., Girinsky, T., Raemaekers, J.M.M., and Henry-Amar, M.

Abstract

Item does not contain fulltext, PURPOSE: In early-stage Hodgkin's lymphoma (HL), subtotal nodal irradiation (STNI) and combined chemotherapy/radiotherapy produce high disease control rates but also considerable late toxicity. The aim of this study was to reduce this toxicity using a combination of low-intensity chemotherapy and involved-field radiotherapy (IF-RT) without jeopardizing disease control. PATIENTS AND METHODS: Patients with stage I or II HL were stratified into two groups, favorable and unfavorable, based on the following four prognostic factors: age, symptoms, number of involved areas, and mediastinal-thoracic ratio. The experimental therapy consisted of six cycles of epirubicin, bleomycin, vinblastine, and prednisone (EBVP) followed by IF-RT. It was randomly compared, in favorable patients, to STNI and, in unfavorable patients, to six cycles of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV hybrid) and IF-RT. RESULTS: Median follow-up time of the 722 patients included was 9 years. In 333 favorable patients, the 10-year event-free survival rates (EFS) were 88% in the EBVP arm and 78% in the STNI arm (P = .0113), with similar 10-year overall survival (OS) rates (92% v 92%, respectively; P = .79). In 389 unfavorable patients, the 10-year EFS rate was 88% in the MOPP/ABV arm compared with 68% in the EBVP arm (P < .001), leading to 10-year OS rates of 87% and 79%, respectively (P = .0175). CONCLUSION: A treatment strategy for early-stage HL based on prognostic factors leads to high OS rates in both favorable and unfavorable patients. In favorable patients, the combination of EBVP and IF-RT can replace STNI as standard treatment. In unfavorable patients, EBVP is significantly less efficient than MOPP/ABV.

Published
2006

40. Quality control of involved-field radiotherapy in patients with advanced Hodgkin's lymphoma (EORTC 20884).

Author

Aleman, B., Girinsky, T., Maazen, R.W.M. van der, Strijk, S.P., Meijnders, P., Bortolus, R., Olofsen-van Acht, M.J., Lybeert, M.L., Lievens, Y., Eghbali, H., Noordijk, E.M., Tomsic, R., Meerwaldt, J.H., Poortmans, P.M.P., Smit, W.G., Pinna, A., Henry-Amar, M., Raemaekers, J.M.M., Aleman, B., Girinsky, T., Maazen, R.W.M. van der, Strijk, S.P., Meijnders, P., Bortolus, R., Olofsen-van Acht, M.J., Lybeert, M.L., Lievens, Y., Eghbali, H., Noordijk, E.M., Tomsic, R., Meerwaldt, J.H., Poortmans, P.M.P., Smit, W.G., Pinna, A., Henry-Amar, M., and Raemaekers, J.M.M.

Abstract

Contains fulltext : 48236.pdf (publisher's version ) (Closed access), PURPOSE: To evaluate the impact of the quality of involved-field radiotherapy (IFRT) on clinical outcome in patients with advanced Hodgkin's lymphoma (HL) in complete remission (CR) after six to eight cycles of mechlorethamine, vincristine, procarbazine, prednisone-doxorubicin, bleomycin, and vinblastine (MOPP-ABV) chemotherapy. METHODS AND MATERIALS: A retrospective review of clinical and radiologic data, radiation charts, simulator films, and megavoltage (MV) photographs was performed. IFRT consisted of 24 Gy to all initially involved nodal areas and 16-24 Gy to all initially involved extranodal sites. Major violations were defined as no or only partial irradiation of an originally involved area, or a total dose <90% of the prescribed dose. RESULTS: Of the 739 patients who were enrolled in the trial between 1989 and 2000, 57% achieved a CR; 152 of 172 patients randomized to IFRT actually received radiotherapy; and in 135 patients, quality control was performed. The overall major violation rate was 47%, predominantly concerning target volumes. The total dose was correct in 81% of the patients. After a median follow-up of 6.5 years, there was no difference in cumulative failure rate between patients with or without major violations. There was no relationship between incidence or site of relapse and major protocol violations. CONCLUSION: In advanced-stage HL patients in complete remission after six to eight cycles of MOPP-ABV, the outcome was not influenced by violation of the radiotherapy protocol.

Published
2005

46. Involved-field radiotherapy for advanced Hodgkin's lymphoma.

Author

Aleman, B., Raemaekers, J.M.M., Tirelli, U., Bortolus, R., Veer, M.B. van 't, Lybeert, M.L., Keuning, J.J., Carde, P., Girinsky, T., Maazen, R.W.M. van der, Tomsic, R., Vovk, M., Hoof, A. van, Demeestere, G., Lugtenburg, P., Thomas, J., Schroyens, W., Boeck, K. de, Baars, J.W., Kluin-Nelemans, H.C., Carrie, C., Aoudjhane, M., Bron, D., Eghbali, H., Smit, W.G., Meerwaldt, J.H., Hagenbeek, A., Pinna, A., Henry-Amar, M., Aleman, B., Raemaekers, J.M.M., Tirelli, U., Bortolus, R., Veer, M.B. van 't, Lybeert, M.L., Keuning, J.J., Carde, P., Girinsky, T., Maazen, R.W.M. van der, Tomsic, R., Vovk, M., Hoof, A. van, Demeestere, G., Lugtenburg, P., Thomas, J., Schroyens, W., Boeck, K. de, Baars, J.W., Kluin-Nelemans, H.C., Carrie, C., Aoudjhane, M., Bron, D., Eghbali, H., Smit, W.G., Meerwaldt, J.H., Hagenbeek, A., Pinna, A., and Henry-Amar, M.

Abstract

Contains fulltext : 143691.pdf (publisher's version ) (Open Access), BACKGROUND: The use of involved-field radiotherapy after chemotherapy for advanced Hodgkin's lymphoma is controversial. METHODS: We randomly assigned patients with previously untreated stage III or IV Hodgkin's lymphoma who were in complete remission after hybrid chemotherapy with mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV) to receive either no further treatment or involved-field radiotherapy. Radiotherapy consisted of 24 Gy to all initially involved nodal areas and 16 to 24 Gy to all initially involved extranodal sites. Patients in partial remission were treated with 30 Gy to nodal areas and 18 to 24 Gy to extranodal sites. RESULTS: Of 739 patients, 421 had a complete remission; 161 of these patients were assigned to no further treatment, and 172 to involved-field radiotherapy. The median follow-up was 79 months. The five-year event-free survival rate was 84 percent in the group that did not receive radiotherapy and 79 percent in the group that received involved-field radiotherapy (P=0.35). The five-year overall survival rates were 91 and 85 percent, respectively (P=0.07). Among the 250 patients in partial remission after chemotherapy, the five-year event-free and overall survival rates were 79 and 87 percent, respectively. CONCLUSIONS: Involved-field radiotherapy did not improve the outcome in patients with advanced-stage Hodgkin's lymphoma who had a complete remission after MOPP-ABV chemotherapy. Radiotherapy may benefit patients with a partial response after chemotherapy.

Published
2003

50. Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials

Author

van der Kaaij, M. A.E., primary, Heutte, N., additional, van Echten-Arends, J., additional, Raemaekers, J. M.M., additional, Carde, P., additional, Noordijk, E. M., additional, Ferme, C., additional, Thomas, J., additional, Eghbali, H., additional, Brice, P., additional, Bonmati, C., additional, Henry-Amar, M., additional, and Kluin-Nelemans, H. C., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results